Compare SHIM & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SHIM | FHTX |
|---|---|---|
| Founded | 1990 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Medicinal Chemicals and Botanical Products |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 160.8M | 173.4M |
| IPO Year | 2023 | 2020 |
| Metric | SHIM | FHTX |
|---|---|---|
| Price | $3.10 | $1.90 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 10 |
| Target Price | $7.00 | ★ $9.89 |
| AVG Volume (30 Days) | 96.7K | ★ 997.2K |
| Earning Date | 11-12-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 81.95 | 25.32 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $492,844,000.00 | $30,909,000.00 |
| Revenue This Year | $1.41 | N/A |
| Revenue Next Year | $20.36 | $15.98 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 2.63 | ★ 36.75 |
| 52 Week Low | $1.95 | $1.79 |
| 52 Week High | $6.76 | $7.61 |
| Indicator | SHIM | FHTX |
|---|---|---|
| Relative Strength Index (RSI) | 40.13 | 12.25 |
| Support Level | $2.45 | N/A |
| Resistance Level | $4.09 | $5.35 |
| Average True Range (ATR) | 0.18 | 0.28 |
| MACD | -0.01 | -0.16 |
| Stochastic Oscillator | 33.09 | 5.72 |
Shimmick Corp is engaged in delivering turnkey infrastructure solutions that strengthen critical markets across water, energy, climate resiliency, and sustainable transportation. It selectively focuses on the following types of infrastructure projects: Water Treatment, Water Resources, and Other Critical Infrastructure. In water treatment projects the company expands, rehabilitates, upgrades, builds and rebuilds water and wastewater treatment infrastructure. In Other Critical Infrastructure projects, It builds, retrofits, expands, rehabilitates, operates, and maintains critical infrastructure, including mass transit, bridges, and military infrastructure. The company has one operating and reportable segment: infrastructure solutions. All of its revenue is derived from the United States.
Foghorn Therapeutics Inc is a clinical stage, precision therapeutics biotechnology company focused on pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression through selectively targeting the chromatin regulatory system. Its proprietary platform is designed to provide an integrated, mechanistic understanding of interactions within the chromatin regulatory system, supporting the identification and validation of potential therapeutic targets. The company's flagship program is FHD-909.